Barriers to Chimeric Antigen Receptor T-Cell Therapy

JAMA Oncol. 2025 May 15:e251127. doi: 10.1001/jamaoncol.2025.1127. Online ahead of print.

Yannis K Valtis^{1

2}, Kuo-Kai Chin², David Nemirovsky³, Sean M Devlin³, Meira Yisraeli Salman², Leora Boussi², Briana Cadzin¹, Carina McLoughlin¹, Elizabeth Cathcart¹, Paul Davis¹, Chelsea Brooklyn¹, Todd Goldstein¹, Chris Famulare², Gunjan L Shah^{1

4}, Moneeza Walji⁴, Michael Scordo^{1

4

5}, Alexander P Boardman^{1

6}, Roni Shouval^{1

4}, Eytan M Stein², Mark B Geyer^{1

2

5}, Sham Mailankody^{1

7}, M Lia Palomba^{1

6}, Saad Z Usmani^{1

7}, Gilles Salles⁶, Sergio A Giralt^{1

4}, Miguel-Angel Perales^{1

4}, Jae H Park^{1

2}

¹ Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Biostatistics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Department of Medicine, Weill Cornell Medical College, New York, New York.
⁶ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁷ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

Plain language summary

This cohort study examines barriers to access of CAR T-cell therapy among patients with hematologic cancer referred for this treatment.